Turn this list into an evaluation

Each entry is an FDA submission, not a distinct commercial offer. Inspect the exact record before comparing evidence, asking for a quote or planning an integration.

Prepare with a buyer guide:

Clinical guide links appear when this list contains a current reviewed example. They do not classify or endorse the other entries. All buyer guides · Compare exact records · Documented families

FDA-cleared K251527

Brain WMH

Quantib BV

Authorized purpose: Brain WMH automatically labels, visualizes, and volumetrically quantifies white-matter hyperintensities from T2w FLAIR brain MR and returns segmentations, overlays, and measurements as complementary information for trained professionals and quantitative reporting in the labeled population.

Modality
MRI
Anatomy
Brain; white matter hyperintensities
Decision
2025-09-25
FDA-cleared K230772

Quantib Prostate

Quantib BV

Authorized purpose: Support trained medical professionals in processing, visualizing, editing, and interpreting prostate MR studies, including structured PI-RADS scoring; diagnosis must not be made solely from the software analysis.

Modality
MRI
Anatomy
Prostate, prostatic sub-regions, and user-selected potential lesions.
Decision
2023-04-17
FDA-cleared K221106

Quantib Prostate

Quantib BV

Authorized purpose: Quantib Prostate versions 1.0 and 2.0 provide processing, visualization, editing, registration, mathematical or statistical analysis, semi-automatic segmentation, volume computation, and PI-RADS workflow support for prostate MRI. The software provides information that may assist trained medical professionals in interpreting prostate MR studies, and diagnosis must not be made solely from its analysis.

Modality
MRI
Anatomy
Prostate; prostate and prostatic sub-regions
Decision
2022-05-13
FDA-cleared K202501

Quantib Prostate

Quantib BV

Authorized purpose: Quantib Prostate is image post-processing software for processing, visualizing, and editing prostate MRI images. It supports registered multiparametric-MRI viewing, optional combined-image visualization, semi-automatic anatomical segmentation, volume computation, manual editing, and a structured PI-RADS workflow to assist trained medical professionals interpreting prostate MR studies; diagnosis should not be made solely from its analysis.

Modality
MRI
Anatomy
Prostate
Decision
2020-10-11
FDA-cleared K182564

Quantib ND

Quantib BV

Authorized purpose: Quantib ND is software for the labeled brain MRI image-analysis workflow, providing release-specific visualization, measurements, or decision-support outputs for professional review.

Modality
MRI
Anatomy
Brain
Decision
2018-12-27
FDA-cleared K173939

Quantib Brain

Quantib BV

Authorized purpose: Automatic brain-structure labeling, visualization, volumetric quantification, and WMH-candidate assessment as complementary information for trained professionals evaluating MR brain images and preparing quantitative reports.

Modality
MRI
Anatomy
Brain structures including grey matter, white matter, cerebrospinal fluid, intracranial volume, and white matter hyperintensity candidates
Decision
2018-03-09
FDA-cleared K163013

Quantib Brain 1.2

Quantib BV

Authorized purpose: Automatic labeling, visualization, and volumetric quantification of segmentable brain structures from MR images; visualizes and quantifies WMH candidates and provides complementary information for trained medical professionals evaluating MR brain images and preparing quantitative reports.

Modality
MRI
Anatomy
Brain structures, including grey matter, white matter, cerebrospinal fluid, and white-matter-hyperintensity candidates.
Decision
2017-01-06
FDA-cleared K153351

Quantib Brain 1

QUANTIB BV

Authorized purpose: Automatic labeling, visualization, and volumetric quantification of segmentable brain structures from MR images; visualizes and quantifies WMH candidates and provides complementary information for trained medical professionals evaluating MR brain images and preparing quantitative reports.

Modality
MRI
Anatomy
Brain structures, including grey matter, white matter, cerebrospinal fluid, and white-matter-hyperintensity candidates.
Decision
2016-06-17